Parenteral nutrition emulsion inhibits CYP3A4 in an iPSC derived liver organoids testing platform
Journal of Pediatric Gastroenterology and Nutrition · 2024
DOI: 10.1002/jpn3.12195 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024. Verfasst von Sean P Harrison und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Research, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Organoids, Cytochrome P-450 CYP3A, Induced Pluripotent Stem Cells, Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Council of Norway, FRIPRO, UiO:Life Science.
Abstract (Originalsprache)
Objectives
Parenteral nutrition (PN) is used for patients of varying ages with intestinal failure to supplement calories. Premature newborns with low birth weight are at a high risk for developing PN associated liver disease (PNALD) including steatosis, cholestasis, and gallbladder sludge/stones. To optimize nutrition regimens, models are required to predict PNALD.
Methods
We have exploited induced pluripotent stem cell derived liver organoids to provide a testing platform for PNALD. Liver organoids mimic the developing liver and contain the different hepatic cell types. The organoids have an early postnatal maturity making them a suitable model for premature newborns. To mimic PN treatment we used medium supplemented with either clinoleic (80% olive oil/20% soybean oil) or intralipid (100% soybean oil) for 7 days.
Results
Homogenous HNF4a staining was found in all organoids and PN treatments caused accumulation of lipids in hepatocytes. Organoids exhibited a dose dependent decrease in CYP3A4 activity and expression of hepatocyte functional genes. The lipid emulsions did not affect overall organoid viability and glucose levels had no contributory effect to the observed results.
Conclusions
Liver organoids could be utilized as a potential screening platform for the development of new, less hepatotoxic PN solutions. Both lipid treatments caused hepatic lipid accumulation, a significant decrease in CYP3A4 activity and a decrease in the RNA levels of both CYP3A4 and CYP1A2 in a dose dependent manner. The presence of high glucose had no additive effect, while Clinoleic at high dose, caused significant upregulation of interleukin 6 and TLR4 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Research, Oslo University Hospital, Oslo, Norway.
- Hybrid Technology Hub-Center of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
- Research, Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
- Department of Haematology, Oslo University Hospital, Oslo, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Förderung
- Research Council of Norway
- FRIPRO
- UiO:Life Science
Zitieren
APA
Harrison, S. P., Baumgarten, S. F., Chollet, M. E., Stavik, B., Bhattacharya, A., Almaas, R., & Sullivan, G. J. (2024). Parenteral nutrition emulsion inhibits CYP3A4 in an iPSC derived liver organoids testing platform. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12195
Vancouver
Harrison SP, Baumgarten SF, Chollet ME, Stavik B, Bhattacharya A, Almaas R, et al. Parenteral nutrition emulsion inhibits CYP3A4 in an iPSC derived liver organoids testing platform. Journal of Pediatric Gastroenterology and Nutrition. 2024. doi:10.1002/jpn3.12195
BibTeX
@article{Harrison2024,
author = {Harrison, Sean P and Baumgarten, Saphira F and Chollet, Maria E and Stavik, Benedicte and Bhattacharya, Anindita and Almaas, Runar and Sullivan, Gareth J},
title = {Parenteral nutrition emulsion inhibits CYP3A4 in an iPSC derived liver organoids testing platform},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
doi = {10.1002/jpn3.12195}
}
EUVIMED